Research programme: autoimmune disease therapy - Trubion PharmaceuticalsAlternative Names: Autoimmune disease therapy research programme - Trubion Pharmaceuticals; TRU-017
Latest Information Update: 25 Jun 2009
At a glance
- Originator Trubion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 18 Jan 2005 Preclinical trials in Autoimmune disorders in USA (unspecified route)